JP6672516B2 - Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 - Google Patents

Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 Download PDF

Info

Publication number
JP6672516B2
JP6672516B2 JP2019142108A JP2019142108A JP6672516B2 JP 6672516 B2 JP6672516 B2 JP 6672516B2 JP 2019142108 A JP2019142108 A JP 2019142108A JP 2019142108 A JP2019142108 A JP 2019142108A JP 6672516 B2 JP6672516 B2 JP 6672516B2
Authority
JP
Japan
Prior art keywords
antibody
days
dose
pharmaceutical composition
stage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019142108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020019769A (ja
JP2020019769A5 (enExample
Inventor
賢治 四宮
賢治 四宮
圭介 五反田
圭介 五反田
純一 西村
純一 西村
エリカ ウィンター
エリカ ウィンター
ジョイ シー． シュー
ジョイ シー． シュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2020019769A publication Critical patent/JP2020019769A/ja
Publication of JP2020019769A5 publication Critical patent/JP2020019769A5/ja
Application granted granted Critical
Publication of JP6672516B2 publication Critical patent/JP6672516B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019142108A 2018-08-01 2019-08-01 Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 Active JP6672516B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862713211P 2018-08-01 2018-08-01
US62/713,211 2018-08-01
US201862764952P 2018-08-17 2018-08-17
US62/764,952 2018-08-17
US201862760204P 2018-11-13 2018-11-13
US62/760,204 2018-11-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020025071A Division JP6672533B1 (ja) 2018-08-01 2020-02-18 Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法

Publications (3)

Publication Number Publication Date
JP2020019769A JP2020019769A (ja) 2020-02-06
JP2020019769A5 JP2020019769A5 (enExample) 2020-03-19
JP6672516B2 true JP6672516B2 (ja) 2020-03-25

Family

ID=67660420

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019142108A Active JP6672516B2 (ja) 2018-08-01 2019-08-01 Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
JP2020025071A Active JP6672533B1 (ja) 2018-08-01 2020-02-18 Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
JP2020036818A Pending JP2020079331A (ja) 2018-08-01 2020-03-04 Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
JP2025018896A Pending JP2025065367A (ja) 2018-08-01 2025-02-07 Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020025071A Active JP6672533B1 (ja) 2018-08-01 2020-02-18 Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
JP2020036818A Pending JP2020079331A (ja) 2018-08-01 2020-03-04 Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
JP2025018896A Pending JP2025065367A (ja) 2018-08-01 2025-02-07 Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法

Country Status (23)

Country Link
US (1) US20210301004A1 (enExample)
EP (2) EP3829628B1 (enExample)
JP (4) JP6672516B2 (enExample)
KR (5) KR20210037743A (enExample)
CN (1) CN112512563A (enExample)
AU (2) AU2019315213B2 (enExample)
BR (1) BR112021001655A2 (enExample)
CA (1) CA3107618A1 (enExample)
CR (1) CR20210103A (enExample)
DE (1) DE112019003835T5 (enExample)
ES (1) ES2980137T3 (enExample)
HR (1) HRP20240823T1 (enExample)
HU (1) HUE067057T2 (enExample)
IL (2) IL280475B2 (enExample)
MX (2) MX2021000516A (enExample)
MY (1) MY210523A (enExample)
PH (1) PH12021550226A1 (enExample)
PL (1) PL3829628T3 (enExample)
RS (1) RS65630B1 (enExample)
SG (1) SG10202002898RA (enExample)
SM (1) SMT202400271T1 (enExample)
TW (2) TWI701041B (enExample)
WO (1) WO2020027279A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2896631A1 (en) 2000-10-10 2015-07-22 Genentech, Inc. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
ES2283594T5 (es) 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
WO2014119969A1 (ko) * 2013-01-31 2014-08-07 서울대학교 산학협력단 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법
BR112017011235A2 (pt) * 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CA2972393A1 (en) * 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
EP3402816A1 (en) 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
WO2017132259A1 (en) 2016-01-25 2017-08-03 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
CN118512588A (zh) * 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
CN111683672A (zh) * 2017-12-04 2020-09-18 Ra制药公司 补体活性调节剂

Also Published As

Publication number Publication date
DE112019003835T5 (de) 2021-05-27
CA3107618A1 (en) 2020-02-06
EP3829628C0 (en) 2024-05-15
TW202024128A (zh) 2020-07-01
KR20210037743A (ko) 2021-04-06
EP3829628B1 (en) 2024-05-15
JP6672533B1 (ja) 2020-03-25
JP2020019769A (ja) 2020-02-06
JP2020079331A (ja) 2020-05-28
KR20240115904A (ko) 2024-07-26
KR20200033225A (ko) 2020-03-27
WO2020027279A1 (en) 2020-02-06
PH12021550226A1 (en) 2021-10-11
BR112021001655A2 (pt) 2021-05-04
TWI704157B (zh) 2020-09-11
AU2019315213B2 (en) 2024-05-02
TW202019467A (zh) 2020-06-01
JP2020073608A (ja) 2020-05-14
MY210523A (en) 2025-09-29
AU2019315213A1 (en) 2021-03-25
EP4445913A2 (en) 2024-10-16
EP3829628A1 (en) 2021-06-09
CN112512563A (zh) 2021-03-16
SG10202002898RA (en) 2020-05-28
RS65630B1 (sr) 2024-07-31
TWI701041B (zh) 2020-08-11
MX2021000516A (es) 2021-04-12
KR20210038697A (ko) 2021-04-07
IL280475B2 (en) 2026-04-01
IL280475A (en) 2021-03-01
US20210301004A1 (en) 2021-09-30
HUE067057T2 (hu) 2024-09-28
JP2025065367A (ja) 2025-04-17
AU2024205486A1 (en) 2024-08-22
IL280475B1 (en) 2025-12-01
HRP20240823T1 (hr) 2024-09-27
PL3829628T3 (pl) 2024-08-19
EP4445913A3 (en) 2025-01-01
MX2025010400A (es) 2025-10-01
KR20200033348A (ko) 2020-03-27
CR20210103A (es) 2021-03-22
IL324626A (en) 2026-01-01
SMT202400271T1 (it) 2024-07-09
ES2980137T3 (es) 2024-09-30

Similar Documents

Publication Publication Date Title
JP7581292B2 (ja) Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
JP6672533B1 (ja) Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
RU2786053C2 (ru) Фармацевтическая композиция для применения для лечения или предупреждения с5-связанного заболевания и способ лечения или предупреждения с5-связанного заболевания
HK40040906A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191225

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191225

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200304

R150 Certificate of patent or registration of utility model

Ref document number: 6672516

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250